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Available online 1 October 2016In addition to oncogenic drivers, signaling nodes can critically modulate cancer-related cellular networks to
strength tumor hallmarks.We identify G-protein-coupled receptor kinase 2 (GRK2) as a relevant player in breast
cancer. GRK2 is up-regulated in breast cancer cell lines, in spontaneous tumors inmice, and in a proportion of in-
vasive ductal carcinoma patients. Increased GRK2 functionality promotes the phosphorylation and activation of
the Histone Deacetylase 6 (HDAC6) leading to de-acetylation of the Prolyl Isomerase Pin1, a central modulator
of tumor progression, thereby enhancing its stability and functional interactionwith keymitotic regulators. Inter-
estingly, a correlation between GRK2 expression and Pin1 levels and de-acetylation status is detected in breast
cancer patients. Activation of the HDAC6-Pin1 axis underlies the positive effects of GRK2 on promoting growth
factor signaling, cellular proliferation and anchorage-independent growth in both luminal and basal breast can-
cer cells. Enhanced GRK2 levels promote tumor growth inmice, whereas GRK2 down-modulation sensitizes cells
to therapeutic drugs and abrogates tumor formation. Our data suggest that GRK2 acts as an important onco-mod-
ulator by strengthening the functionality of key players in breast tumorigenesis such as HDAC6 and Pin1.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acetylation1. Introduction
Malignant features such as sustained proliferative signaling, refrac-
toriness to growth suppressors, resistance to cell death or aberrant mo-
tility and metastasis, can be triggered by a variety of distinctive
mutations and signaling adaptations (Hanahan and Weinberg, 2011).
This complexity translates into phenotypic variability among tumors.
A prototypic example is breast cancer, a heterogeneous disease
encompassing different histopathological entities with distinct molecu-
lar signatures, genetic and genomic variations (Bertos and Park, 2011).
Ductal carcinomas (circa 80% of all breast cancers) are grouped in sever-
al types based on the estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2 ora Molecular, Centro de Biología
Autónoma de Madrid, 28049
nela@cbm.csic.es (P. Penela).
ntre, 28029 Madrid, Spain.
. This is an open access article underERBB2). The most common is the luminal type characterized by ER+
and (or) PR+ with a HER− (A subtype) or HER+ (B subtype) status.
Along with the luminal B subtype, the HER2ERBB2-positive (ER and
PR negative) and basal-like tumors lacking ER, PR and ERBB2 expression
(triple negative) exhibit the worst prognosis (Bertos and Park, 2011;
Hanahan and Weinberg, 2011). Enhanced activation of the RAS-mito-
gen activated protein kinase (MAPK) pathway triggered by ampliﬁca-
tion or up-regulation of growth factor receptors (ERBB2, IGF1R, EGFR),
ER activation and alterations in the PI3K-AKT pathway are major con-
tributors to the uncontrolled cellular proliferation and increased surviv-
al of breast tumor cells (Saini et al., 2013).
In addition to these oncogenic drivers, signaling nodes can act as
cancer-associated factors by cooperating with oncogene-governed
pathways or participating in compensatory transduction networks to
strengthen tumor properties. G-protein-coupled receptor kinase 2
(GRK2) is emerging as one of such key nodes. Besides its canonical
role in the desensitization of G protein-coupled receptors (GPCR)
(Penela et al., 2010a; Premont and Gainetdinov, 2007), GRK2 is a posi-
tive effector of certain GPCR and receptor-tyrosine kinases (RTK)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to aberrant survival, cellular growth and invasivemotility in a variety of
cancer cells (Lappano and Maggiolini, 2011). GRK2 has been identiﬁed
as a rate-limiting mediator of MAPK activation and growth signaling
triggered by some tumor-related GPCRs (Lipfert et al., 2013; Penela et
al., 2008; Philipp et al., 2008). GPCRs can also trans-activate the EFGR
by means of the GRK-β-arrestin-axis (Rozengurt, 2007). These effects
may be explained by the ability of GRK2 to phosphorylate or dynamical-
ly interact with important modulators engaged along the MAPK path-
way (Deiss et al., 2012; Penela et al., 2010b, 2008). Moreover, other
relevant GRK2-interacting proteins or substrates are key players in the
cellular stress response and survival (Lafarga et al., 2012b; Robinson
and Pitcher, 2013) and references therein).
Despite such potential connectivity to signaling pathways related to
cell transformation, and available data showing altered GRK2 levels in
some tumoral contexts (reviewed in Evron et al. (2012), Penela et al.
(2010a)) a comprehensive study of the role of GRK2 in tumor formation
and progression has not been addressed. We report here that GRK2
levels are altered in breast luminal tumors and that increased GRK2
functionality in diverse breast cancer cell types represents a driving sig-
naling event in the acquisition and maintenance of tumoral prolifera-
tion and survival, by mechanisms involving the potentiation of
Histone Deacetylase 6 (HDAC6) function and the modulation of Pin1
(Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) acetylation
status and functionality.
2. Materials and Methods
2.1. Cell Culture, Cellular Treatments and Antibodies
All tumoral and non-tumoral breast cells were obtained from the
American Type Culture Collection. Details onmedium conditions, trans-
fectionmethods, reagents for cellular treatments and antibodies utilized
can be found in Supplemental Methods.
2.2. Cell Proliferation and Viability Assays
Cell proliferation was measured using the CellTiter96®AQueaous
Non-Radioactive Cell Proliferation Assay according to the
manufacturer's protocol (Promega). In addition, cell viability was also
monitored in real-time assays using the xCELLigence System (RocheAp-
plied Science) following the manufacturer's guidelines.
2.3. Mammary Tissue from Animal Models and Breast Cancer Patients
Mammary glands from 9-weeks old Myr-AKT transgenic mice and
wild type littermates and paired non-tumoral and tumoral glands
from 6 to 9 weeks old transgenic FVB-N-TgMMTV-HER2 mice were re-
moved and snap-frozen. Human normal breast tissue and inﬁltrating
ductal carcinoma samples were obtained from patients recruited at
theHospital Universitario La Paz (Madrid, Spain).Mice andhuman sam-
ples were processed as detailed in Supplemental Methods.
2.4. Colony Formation Assay
Tetracycline- or vehicle induced MCF7 Tet-on wt-GRK2 and GRK2-
K220R cells were seeded in a soft agar medium, and cells were then
ﬁxed with methanol and stained with 0.005% Crystal Violet for subse-
quent analysis as detailed in Supplemental Methods.
2.5. Statistics
Data in all ﬁgures are expressed as mean ± SEM or SD as indicated.
All resultswere conﬁrmed in at least 2 separate experiments. Data were
analyzed using Student's t-test. Two-tailed p b 0.05was considered sta-
tistically signiﬁcant. Statistical correlations obtained from samples ofpatients were analyzed using Pearson Test or a quadratic regression lin-
ear model with p b 0.05 considered as signiﬁcant.
Protein and DNA arrays, western blot analysis and protein data nor-
malizations, GST pulldown assays, protease-coupled peptidyl-prolyl
isomerase assays, in vivo tumor implantation, immunohistochemical
assays and study approval are described in the Supplemental Methods
section.
3. Results
3.1. GRK2 protein expression is upregulated in breast cancer cell lines and
cancer-prone animal models
We examined GRK2 expression in a panel of breast tumor cell lines
representative of molecular features found in many of the primary
tumor subtypes (Vargo-Gogola and Rosen, 2007). Luminal MDA-
MB361, T47D andMCF7 cells expressed 3- to 10-fold higher GRK2 levels
than non-transformed MCF10A and 184B5 lines (Fig. 1A). Conversely,
total GRK2 levels were not increased in basal breast cancer-derived
MDA-MB-231, MDA-MB157 and Hs578T cells. Enhanced GRK2 was
also detected in MDA-MB468 cells, usually classiﬁed in the basal A sub-
type (Kao et al., 2009), but that share features with the luminal molec-
ular phenotype (see below).
Interestingly, while GRK2 is upregulated in luminal cells irrespective
of their p53 status (Fig. S1A), enhanced GRK2 concurswith eithermuta-
tional activation of PIK3CA or inactivation of PTEN (Fig. 1B), and corre-
lates with increased activation of the AKT pathway (Fig. 1C), a
frequent feature of human luminal breast tumors (Eroles et al., 2012).
Thesemutations are not displayed by the basal cells in our panel, except
for MDA-MB468, which shows increased GRK2, consistent with previ-
ous data (Salcedo et al., 2006).
Elevated GRK2 was present in cells ER-PR+ (MDA-MB361, T47D
and MCF7) and (or) displaying ampliﬁcation of the EGFR (MDA-
MB468) or HER2 (MDA-MB361) receptors (Fig. 1B), all of them contexts
able to trigger PI3K-AKT activation (Renoir et al., 2013; Roskoski, 2014).
Estrogen withdrawal promoted a decrease of GRK2 in both MCF7 and
T47D ER+ cells (Fig. 1D), whereas estrogen exposure caused circa 2-
fold increase (Fig. 1E). Moreover, GRK2 decayed in ER+ non-trans-
formed 184B5 cells challenged with the estrogen antagonist tamoxifen,
but not in tamoxifen-refractory MCF7 and T47D lines (Fig. S1B, C). Co-
transfection of HER2 and Ras-V12, known to cooperatively induce
mammary cell transformation (Wulf et al., 2004) increased both GRK2
protein and AKT stimulation in the non-malignant MCF10A and 184B5
cells (Fig. S1D) whereas epidermal growth factor receptor (EGFR) inhi-
bition markedly reduced GRK2 levels and AKT activation in EGFR-over-
expressing MDA-MB468 cells (Fig. 1F).
These results suggested that different signaling pathways altered in
luminal breast cancer cell lines converge in promoting anAKT-mediated
increased in GRK2 levels. Consistently, GRK2 expression was increased
speciﬁcally in those mammary glands of transgenic MMTV-HER2 mice
that spontaneously develop tumors (Fig. 1G), in parallel with higher ac-
tivation of AKT, and in mammary glands of transgenic mice expressing
myr-AKT (Fig. 1H), a constitutively active membrane-bound construct
(Blanco-Aparicio et al., 2007).
3.2. GRK2-dependent regulation of HDAC6 strengthens growth factor-trig-
gered signaling pathways in breast cells
Cell lineswith enhanced GRK2 levels also displayed increased prolif-
eration rates and expression of key proliferation markers compared to
non-transformed and basal cells (Fig. S2a, b). Consistentwith the notion
that GRK2 up-regulation was not a mere bystander but was playing a
role in the acquisition or strengthening of oncogenic properties, GRK2
overexpression in either non-transformed MCF10A (Fig. S3a, b) or
184B5 (Fig. S3c–f) cells promoted a signiﬁcant increase in the levels of
the mitotic entry marker pHis3 as well as of Pin1, a pivotal regulator
Fig. 1. Luminal breast tumors oncogenic pathways promote increased GRK2 protein levels in cellular and animal models. (A) Western blot analysis of GRK2 expression levels relative to
184B5 cells in non-transformed (NT), “luminal-like” and “basal-like” transformed breast cancer cells. (B) Molecular features of cell lines used in (A):+, presence;−, absence; null,
homozygous deletion. (C) Immunoblot analysis of pSer473- AKT and pan-AKT levels in panel A cell lysates. (d, e) Analysis of GRK2 and HDAC6 expression in luminal breast tumor cells
in control or estrogen-depleted conditions (D), or upon estrogen re-stimulation (E). (f) Levels of GRK2 and AKT activation in MDA-MB-468 cells treated with the EGFR-inhibitor
AG1478. (G, H). Mammary expression of GRK2 and AKT activation in tumor-bearing HER2-transgenic mice (n = 4, g) or MyrAKT1-transgenic animals (n = 2 per group, h) as
compared to normal paired glands or non-transgenic littermates. All data are mean ± SEM, n = 3–4. Actin or GAPDH expression was used as loading control were indicated.
*p b 0.05; **p b 0.01; ***p b 0.001.
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to an extent similar to that of the oncogenic drivers Ras-Her2. Notably,
adenovirus-mediated transduction of wild-type GRK2 in either 184B5
(Fig. S4a) orMCF10A cells (Fig. S4b) potentiated EGF-triggered Ras acti-
vation, whereas a catalytically inactive GRK2-K220R construct did not,
suggesting that GRK2-mediated phosphorylation processes were re-
quired for enhancingmitogenic signaling. Moreover, the already altered
levels of Pin1 and Ras proteins in transformed MCF7 cells were further
increased by extra GRK2 butmarkedly reduced upon its shRNA-mediat-
ed knockdown (Fig. S4c). Further stressing a potential causal effect of
GRK2 activity on Pin1 protein levels, adenovirus-mediated expression
of wild-type GRK2 (but not of the kinase-dead K220R) enhanced Pin1
expression in a different luminal cell line (T47D) or in several basal
breast cancer cells (MDA-MB-231, MDA-MB468 and Hs578T) (Fig.
S4d), whereas an interfering shRNA-GRK2 construct signiﬁcantly di-
minished Pin1 levels in most of these cells.
Remarkably, stable overexpression of GRK2 in 184B5 cells also sig-
niﬁcantly facilitated both mitogenic (ERK1/2) and pro-survival signal-
ing (AKT) in response to heregulin (Fig. S5a) or EGF (Fig. S5b). Similar
consequences were also noted in the time-course and dose-responseFig. 2. GRK2 over-expression potentiates mitogenic signaling pathways in breast cancer cells vi
cells with extra (GRK2 35 clone) or silenced (shGRK2) expression of GRK2. *p b 0.05, **p b 0.
conditions, respectively. (b–c) Analysis of EGF-triggered ERK1/2 and AKT stimulation upon tra
(b), or stable transfection in MDA-MB-231 cells (c). *p b 0.05, **p b 0.01 and ***p b 0.001
HDAC6-wt to HDAC6 mutant-expressing cells. In all panels data are mean ± SEM (n= 3–4). Reffects of EGF in GRK2-overexpressing MCF7 cells in a catalytic-depen-
dent manner (Fig. S6a, b), whereas kinase down-modulation markedly
attenuated EGF signaling (Fig. 2a).
We hypothesized that the cytoplasmic type II histone deacetylase 6
(HDAC6) could play a relevant role underlying these effects. HDAC6
has been associated with malignant transformation in breast cancer
(Li et al., 2013) and its tubulin-deacetylase activity contributes tomain-
tain the EGFR at the plasma membrane, thus promoting sustained acti-
vation of downstream cascades (Deribe et al., 2009; Gao et al., 2010).
We have reported that EGF-induced phosphorylation of GRK2 at S670
by ERK1/2 was required for GRK2-mediated phosphorylation of
HDAC6, in turn promoting full tubulin deacetylase activity (Lafarga et
al., 2012a). Notably, enhanced levels of HDAC6 were detected in the lu-
minal-like breast cancer cells displaying GRK2 up-regulation (Fig. S7a),
while most of both luminal and basal breast cancer cells tested
displayed increased levels of phospho-S670 GRK2 (Fig. S7b), suggesting
that a GRK2-HDAC6 axis could be operative in these cells. Remarkably,
an HDAC6 mutant unable to be phosphorylated by GRK2 (Lafarga et
al., 2012a) blocked the GRK2-triggered increase in EGF-mediated sig-
naling to ERK1/2 in 184B5 cells (Fig. S7c) and led to enhanced levelsa HDAC6. (a) Analysis of both AKT and ERK1/2 responses to 100 ng/ml EGF inMCF7-F5luc
01 and ***p b 0.001, and T p b 0.05, TT p b 0.01 comparing pcDNA3 to shGRK2 and GRK2
nsfection of GFP-HDAC6-wt or GRK2-phosphodefective HDAC6 constructs in MCF7 cells
compared to empty vector-bearing cells and T p b 0.05, TT p b 0.01 for comparison of
epresentative blots are shown.
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sion of this phospho-defective HDAC6 mutant in either MCF7 luminal
(Fig. 2b) or MDA-MB-231 basal cells (Fig. 2c) failed to mimic the en-
hanced EGF signaling promoted by wild-type HDAC6, strongly suggest-
ing that a reinforced GRK2-HDAC6 functional interaction was playing a
role in increasing EGF-modulated cascades in different breast cell types.
3.3. The GRK2-HDAC6 module stimulates Pin1 functionality by triggering
de-acetylation of its lysine 46 residue
The notion that enhanced EGF signaling could be explained by an in-
creased GRK2-dependent HDAC6-triggered deacetylation of α-tubulin
would be consistentwith themarked deacetylation of non-histone sub-
strates reported in breast cancer (Suzuki et al., 2009). However, the ex-
tent of total tubulin deacetylation in our panel of cancer cell lines (Fig.
S8a) did not straightforward correlate with the extent of GRK2 expres-
sion or phosphorylation status. We thus hypothesized that GRK2might
affect the HDAC6-dependent deacetylation of other key factors in the
EGF pathway. As indicated above, GRK2 expression upregulated in dif-
ferent luminal and basal breast cancer cell lines the protein levels of
Pin1 (Fig. S4c, d), a keymitoticmodulator and distal EGF-signaling com-
ponentwhichpositively regulates other downstream factors such as Cy-
clin D1 (Lu, 2003). Interestingly, Pin1 was previously identiﬁed as a
target of acetylation in a large-scale proteomics screen (Choudhary et
al., 2009). Therefore, we addressed whether Pin1 acetylation could be
modulated by HDAC6 in a GRK2-mediated manner. The presence of
HDAC6 inhibitors caused hyperacetylation of endogenous Pin1 (Fig.
S8b) to an extent similar to that of tubulin in MCF7 cells (Fig. S8c), put-
ting forward Pin1 as a target of HDAC6 activity. Stable expression of
extra GRK2 in MCF7 cells markedly reduced the steady-state levels of
Pin1 acetylation, whereas kinase downmodulation promoted the oppo-
site effect (Fig. 3a). Moreover, acetyl-Pin1 decreased progressively in
MCF7 cells correlating with tetracycline-mediated induction of active
GRK2, whereas a kinase-dead mutant promoted increasing accumula-
tion of acetylated Pin (Fig. S8d). Further conﬁrming that catalytic activ-
ity of GRK2 regulates de-acetylation of Pin1, inhibition of GRK2with the
small-molecule Cpmd101 promoted hyper-acetylation of Pin1 and ab-
rogated Pin1 de-acetylation triggered by GRK2 overexpression (Fig.
S8e). Moreover, EGF stimulation caused a rapid decrease of acetyl-
Pin1 levels in MCF7 cells in a GRK2-mediated manner, since extra
GRK2 potentiated deacetylation while an inactive kinase showed the
opposite effect (Fig. 3b). Interestingly, EGF promoted the endogenous
association of Pin1 and HDAC6 in MCF7 cells in parallel to increased
Pin1 de-acetylation (Fig. 3c). Substantiating that GRK2 regulates Pin1
deacetylation through HDAC6 phosphorylation, acetylation of endoge-
nous Pin1 was efﬁciently counteracted by the expression of HDCA6-wt
in both MCF7 (Fig. 3d) and MDA-MB-231 cells (Fig. 3e), while extra
levels of a HDAC6 mutant unable to be phosphorylated by GRK2 had
the opposite effect, leading to a marked increase in the extent of Pin1
acetylation in both cell lines. Overall, these data indicated that Pin1
was speciﬁcally and dynamically deacetylated in breast tumor cells
through a GRK2-dependent activation of HDAC6.
To evaluate the impact of the acetylation status on Pin1 functionali-
ty, we engineered mutations at lysine 46, a residue within the ﬂexible
linker domain of Pin1 previously identiﬁed as the acetyl-acceptor siteFig. 3. GRK2 fosters Pin1 functionality by regulating its acetylation status in a HDAC6-depend
MCF7-F5luc cells stably over-expressing GRK2 or a silencing shRNA-GRK2 construct were d
compared to empty vector, TT p b 0.01 for the indicated comparison (n = 3–4). (b) GRK2 pro
assessed in MCF7tet-GRK2 and MCF7tet-GRK2-K220R cells treated or not with tetracycline
comparing EGF-stimulated tetracycline-induced vs non-induced conditions. (c) EGF-indu
MCF7tet-GRK2wt cells. **p b 0.01 (or #p b 0.05) when compared to unstimulated cells in a tw
HDAC6. Pin1 acetylation decays upon transient (d) or stable (e) over-expression of HDAC6-w
MB-231 (e) cells. (f, g) Prevention of K46-acetylation enhances the binding of Pin1 to mitoti
Nocodazol were pulled-down with GST or GST-Pin1 constructs and analyzed by immunoblott
and mitotic arrest were conﬁrmed by western blot with anti-GST and anti-phospho Histone
***p b 0.001.Representative blots are shown.by mass-spec analysis (Choudhary et al., 2009), that either mimicked
the change in charge linked to acetylation (K-to-Q mutants) or pre-
served the charge by blocking acetylation (K-to-R mutants). Expression
of such constructs conﬁrmed that lysine 46 was the main site for Pin1
acetylation (Fig. S9a). Prevention of acetylation increased the protein
stability of a tagged Pin1 construct (Fig. S9b, c), consistent with the ob-
served effects of GRK2 dosage on Pin1 protein levels (Fig. S3a, c and S4c,
d) and with the GRK2-induced deacetylation of Pin1 (Fig. 3a, b and Fig.
S8d, e). Furthermore, catalytic activity assays indicated that the non-
acetylated GST-Pin1-K46R mutant displayed a 7-fold lower Km and in-
creased Kcat to Km ratio compared to GST-Pin1-K46Q or GST-Pin1-wt
and suggested that deacetylation promotes a higher substrate afﬁnity
and isomerase activity (Fig. S9d, e). Moreover, using a GST-Pin1
pulldown assay in nocodazole-treated MCF7 cells (Fig. 3f), we found
that, compared to GST-Pin1-wt, the acetylation-impaired mutant GST-
Pin1-K46R displayed a two-fold increased ability to bindmitotic protein
monoclonal 2 (MPM-2) antigens, known Pin1 substrates present in mi-
totic cells, particularly within the high molecular weight range. On the
other hand, in contrast to GST-Pin1-Y23A, a WW-domain mutant un-
able to interact with substrates, the acetylation-mimicking K46Qmuta-
tion did not abolish protein binding, suggesting that the status of this
residue acts as a regulatory factor in Pin1 substrate binding. A similar
trend was noted for the mitotic target Polo-like kinase 1 (PLK1) (Fig.
3g), an early trigger of G2/M transition and a key regulator of mitotic
events. Together, these results showed that Pin1 undergoes dynamic
and HDAC6 regulated acetylation-deacetylation and that GRK2-
HDAC6-induced Pin1 deacetylation would enhance protein stability
and functionality.
3.4. GRK2 enhances proliferation and transforming growth properties of
breast cancer cell lines by modulating HDAC6 and Pin1 functionality
We next investigated whether increased GRK2 dosage could endow
breast cells with proliferative advantages in tumor-related contexts.
Non-transformed 184B5 cells overexpressing GRK2 displayed a mark-
edly increased proliferation rate in low-serum conditions compared to
parental cells in a way dependent on GRK2 kinase activity (Fig. S10a,
b). Similarly, increasing GRK2 dosage fostered the already high real-
time growth rate of both MCF7 and MDA-MB-231 transformed cells in
normal serum conditions, whereas the catalytically inactive GRK2 mu-
tant had no effect (Fig. 4a, b). Conversely, GRK2 down-regulation signif-
icantly inhibited proliferation of either these cells or MDA-MB-468
tumoral cells (Fig. 4b and Fig. S10c, d). Such inhibitory effects could
not be rescued by the expression of the inactive GRK2-K220R mutant
(Fig. S10e, f). Interestingly, siRNA-mediated knockdown of HDAC6 ex-
pression suppressed the GRK2-dependent promotion of cell prolifera-
tion in MCF7 cells (Fig. 4c). Further conﬁrming that GRK2-dependent
phosphorylation of HDAC6 is relevant in breast cancer cell proliferation,
expression of wild-type HDAC6 but not the HDAC6-S1060-1062-1068A
mutant strongly potentiatedMDA-MB-231 cell growth (Fig. 4d). Consis-
tent with a role of the GRK2-HDAC6 axis in controlling cell proliferation
via regulation of Pin1 acetylation and functionality, transient expression
of either Pin1 wild-type or Pin1-K64R (permanent deacetylation-mim-
icking, higher functionality mutant) in MCF7 cells previously devoid of
endogenous Pin1 using a mixture of siRNAs, signiﬁcantly fosteredent manner. (a) Effect of GRK2 dosage on Pin1 acetylation status. Levels of acetyl-Pin1 in
etermined as detailed in Materials and Methods. *p b 0.05, **p b 0.01 and ***p b 0.001
motes Pin1 de-acetylation in a catalytic-dependent manner. Pin1 acetylation levels were
for 24 h and stimulated with EGF (100 ng/ml) for the indicated times. *p b 0.05, when
ced co-immunoprecipitation of endogenous HDAC6 and Pin1 in tetracycline-induced
o-tail (or one-tail) t-test analysis (n = 3). (d, e). Effect of GRK2 on Pin1 de-acetylation by
t, but not of an HDAC6 mutant defective in GRK2 phosphorylation, in MCF7 (d) or MDA-
c phospho-proteins. Lysates of MCF7 cells in exponential growth or in mitotic arrest by
ing with anti-MPM2 (f) or anti-PLK1 (g) antibodies. Equal loading of GST fusion proteins
3 antibodies. In these panels data are mean ± SEM, n = 2–5. *p b 0.05, **p b 0.01 and
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mimicking construct)was incompetent to support cellular proliferation.
Interestingly, analysis of changes in the activity of transcription fac-
tors in response to chronic EGF stimulation in parental and GRK2-over-
expressing 184B5 cells suggested a relationship with enhanced Pin1
functionality mediated by extra GRK2 (Fig. S11a–c), whereas p53 was
clearly attenuated in GRK2-overexpressing 184B5 cells in agreement
with our previous ﬁndings (Penela et al., 2010b). Both p53 attenuation
and increased Pin1-Ras functionality favored by enhanced GRK2 could
bolster up cell transformation (Liou et al., 2011; Thomassen et al.,
2008). Consistent with this notion and with the role of these factors in
anchorage-independent cell growth (Hanahan and Weinberg, 2011;
Wulf et al., 2004), induction of wtGRK2 expression strongly increased
(N10-fold after 3-weeks in culture) the ability of MCF7 cells to form col-
onies in non-adherent conditions,whereas the GRK2-K220Rmutant did
not mimic such effect (Fig. 5a–d). Proportion and size of larger colonies
(Fig. 5c, d) also increased at both 1week and 3weeks of culture in wild-
type vs GRK2-K220R-expressing cells. Likewise, adenovirus-mediated
expression ofwild-typeGRK2 inMDA-MB-231 cells potentiated net col-
ony formation in soft-agar as well as the proportion of larger colonies,
while downregulation of GRK2 weakened their transforming pheno-
type (Fig. 5e). Notably, Pin1-knockdown-MCF7 cells transiently ex-
pressing wild-type Pin1 or Pin1-K46R formed a higher number of total
colonies and of larger-size in soft-agar than Pin1-K46Q-expressing
cells (Fig. 5f and Fig. S11d). Furthermore, extra wild-type HDCA6
strengthened the transforming phenotype of MDA-MB-231 cells in a
GRK2-mediated phosphorylation-dependent manner (Fig. 5g). Overall,
these results indicated that GRK2 kinase activity is a strong facilitator
of the processes triggered to promote proliferation in non-anchorage
conditions and to bypass anoikis irrespective of the p53 status and relat-
ed to HDAC6 and Pin1 functionality.
3.5. GRK2 favors survival of breast cancer cells in a kinase activity-depen-
dent manner
Intrinsic and acquired resistance to cell death is another important
feature of cancer progression. The weak apoptotic response of MCF7
cells toward commonly used cytotoxic compounds, as paclitaxel or
etoposide, was potentiated upon GRK2 down-modulation (Fig. S12a–
d). On theother hand, p53 levels and thepro-apoptotic phosphorylation
of p53 at Ser15 (Maclaine andHupp, 2011), were reduced in response to
cytotoxic compounds in cells stably over-expressing GRK2 as compared
to parental cells (Fig. S12e, f).
HDAC6 inhibitors can be used as anti-cancer agents, and pan or se-
lective HDAC6 inhibitors such as suberoylanilide hydroxamic acid
(SAHA) or tubacin, respectively, are able to induce growth inhibition
and apoptosis in different cancer cell types (West and Johnstone,
2014). Consistent with the notion that GRK2 would potentiate HDAC6
activity and cellular survival, the anti-proliferative and death-promot-
ing effects of these inhibitors were attenuated upon overexpression of
functional wt-GRK2 in either 184B5 orMDA-MB-231 cells (Fig. S13a, b).
3.6. GRK2 is upregulated in breast tumor patients and correlates with Pin1
functionality and with prognostic markers
We determined GRK2 expression by western blot analysis in a ran-
domly-collected group of 27 patients with inﬁltrating breast ductal car-
cinoma. An important proportion (41%) of tumor samples (Fig. 6a and
Fig. S14a–c) displayed increased GRK2 protein levels compared to nor-
mal specimens, consistent with recurrent ampliﬁcation or mutation of
the GRK2-upregulating signaling pathways discussed above in the
major luminal A-B and HER2 clinical subtypes of breast primary tumors
(Eroles et al., 2012). Interestingly, AKT activity was up-regulated in a
similar proportion (48%) (Fig. 6b), and a positive correlation was
noted in the GRK2-positive tumors with AKT stimulation status (Fig.
S14d, e). This trend was conﬁrmed by immunohistochemistry analysisin 100% of AKT-positive samples of an independent cohort of 49 meta-
static inﬁltrating ductal carcinomas, in which up-regulated GRK2 was
also detected in 80% of primary tumors from patients that underwent
metastasis (Fig. 6c, d). Interestingly, in the former cohort GRK2 expres-
sion positively correlated with increased tumor size (Fig. 6e) and with
increased signals of the Ki67 proliferationmarker (Fig. 6f), but inversely
with p53-positive samples (Fig. 6h), in agreement with a p53-
downmodulating effect of GRK2. Consistent with a relevant role of
GRK2 in the regulation of Pin1 functionality in breast tumors, enhanced
GRK2 protein levels positively associates with Pin1 expression (Fig. 6h
and S14F), while an inverse non-linear correlation between GRK2 ex-
pression levels and the extent of acetylated-Pin1 was noted in breast
cancer patients, but not in non-tumoral samples (Fig. 6i). Further sub-
stantiating the relevance of the GRK2-HDAC6 axis in Pin1 expression
and functionality in human breast tumors, the occurrence of increased
Pin1 (Pin1+) is higher in GRK2-positive samples, either HDAC6-posi-
tive or -negative, comparing to GRK2 n.c or negative samples (Fig.
S15) in which Pin1-positive and –negative samples are evenly repre-
sented irrespective of HDAC6 levels. These results may suggest that
GRK2 overexpression could efﬁciently mediate deacetylation and pro-
tein stabilization of Pin1 even at low HDAC6 expression levels.
3.7. GRK2 is a relevant modulator of tumor growth in vivo
To test the role of GRK2 in driving ormaintaining tumor development
in vivo,we investigatedwhether xenograft tumor growth inmicewas in-
ﬂuenced by GRK2 levels in human breast cancer cells. Using a doxycy-
cline-dependent inducible expression strategy, we observed that
tumors formed by MCF7 cells over-expressing wtGRK2 (but not those
harboring the inactive K220Rmutant) developed earlier and reached sig-
niﬁcantly higher sizes (Fig. 7a). Staining of sections fromMCF7-wtGRK2-
induced tumors demonstrated an increase in the proliferation marker
Ki67 alongwith a decrease in p53 and cleaved caspase3 immunostaining,
indicative of resistance to apoptosis, whereas no signiﬁcant changeswere
observed in MCF7-K220R-derived tumors (Fig. 7b).
These ﬁndings were conﬁrmed using an alternative experimental
setting using adenoviral vectors. More important, down-regulation of
GRK2 expression completely abrogated the growth of tumors (Fig. 7c),
which display at early time points a substantial reduction in the prolif-
eration marker Ki67 and a marked increase in p53 levels, suggestive of
enhanced apoptosis (Fig. 7d). Simultaneous expression in the silenced
MCF7 cells of the GRK2-K220R mutant did not rescue the blockade of
tumor induction, indicating that kinase activity was required for the
tumor-promoting effect of GRK2 in vivo (Fig. S16a).
Further suggesting a clinical relevance for GRK2 in breast cancer, tu-
mors formed by MCF7-F5Luc cells stably over-expressing wild-type
GRK2 developed earlier and reached higher volume than those promot-
ed by parental cells inmurinemammary glands, an orthotopic model in
which speciﬁc fat-pad stromal interactions with transformed epithelial
cells are recapitulated (Fig. 7e). Conversely, growing of GRK2-knock-
down cells was halted compared to parental cells despite similar initial
engraftment (otherwise hampered in the less permissive xenograft
model), suggesting that expression of GRK2 is required formaintenance
of aberrant growth in the breast tissue.
Interestingly, the ability of GRK2 to modulate tumor growth in vivo
was also detected inmutant p53 contexts. AswithMCF7, tumors induced
bywtGRK2-overexpressingMDA-MB-468 cells (ER-, HER2-,mutated p53
and PTEN) andMDA-MB-231 cells (also triple-negative but non-mutated
PTEN) were slightly higher in size (Fig. S16b, c), whereas kinase down-
modulation markedly inhibited tumor formation (Fig. S16b), suggesting
a more general role for GRK2 in breast cancer development.
4. Discussion
We report that increased GRK2 levels and functionality in either lu-
minal or basal cancer cells can drive the acquisition andmaintenance of
Fig. 4.GRK2 endows transformed breast cells with proliferative advantages. (a, b) Growth of parental, shRNA-GRK2, wt or K220Rmutant GRK2-infectedMCF7 (wt p53) (a), orMDA-MB-
231 (mutant p53) (b) cells in normal culture medium was monitored using the xCELLigence technology as described in Materials and Methods. * or T, p b 0.05 and **p b 0.01 when
compared to control infected cells. (c–d) HDAC6 underlies the growth-promoting effects of GRK2. (c) xCELLigence-based analysis of growth of non-induced or tetracycline-induced
(24 h) GRK2wt-MCF7-Tet cells upon HDAC6 silencing with a pool of siRNAs as detailed in Materials and Methods. *p b 0.05 and ***p b 0.001 (two-tail), when compared to siRNA
control-transfected and untreated cells, #p b 0.05 and ##p b 0.01 (one-tail). Proper knockdown of HDAC6 and induction of GRK2 is shown in a representative blot. (d) Stable
expression of HDAC6-wt but not of the HDAC6-S1060-1062-1068A mutant fosters growth in MDA-MB-231 cells. (e) Acetylation of Pin1 impairs proliferation of tumor cells. Growth of
MCF7 cells co-transfected either with HA-Pin1-wt, HA-Pin1-K64R or HA-Pin1-K46Q and a combination of two speciﬁc Pin1 siRNAs or a control siRNA was determined as above.
*p b 0.05, #p b 0.05, T p b 0.05 in one-tail t-test analysis. Similar expression of Pin1 constructs and knockdown of endogenous Pin1 was conﬁrmed by immunoblot with anti-HA and
anti-Pin1 antibodies. A fragment that co-migrates with endogenous Pin1 is detected with a speciﬁc Pin1 antibody upon HA-Pin1 transfection. In all panels data are mean ± SEM (n= 3).
139L. Nogués et al. / EBioMedicine 13 (2016) 132–145tumoral proliferation and survival. Elevated GRK2 protein levels are de-
tected in different breast cancer cell lines, in tumors developed in
MMTV-HER2 animals, in the mammary gland of Myr-AKT transgenic
mice and in a signiﬁcant proportion of two independent groups of pa-
tients diagnosed with invasive ductal carcinoma, in which luminal sub-
types predominate (Bertos and Park, 2011). Interestingly, the
stimulation of different transduction pathways (estrogen or EGFRreceptors, the Ras-HER2 and PI3K-AKT cascades) known to be hyper-ac-
tivated in luminal and in certain non-luminal types of breast cancer
(Eroles et al., 2012) not only correlates with increased GRK2 levels but
appears to converge in promoting enhanced GRK2 expression in trans-
formed and non-transformed breast epithelial cells.
Our results are consistent with a relevant role for the AKT pathway
in promotingGRK2up-regulation. Cancer cells whereGRK2 is enhanced
Fig. 5. GRK2 favors the anchorage-independent growth of breast tumor cells in a kinase-dependent manner via regulation of HDAC6 and Pin1. (A) Time-course of GRK2 levels in
tetracycline (TET)-induced MCF7tet-GRK2wt or -GRK2-K220R cells. Colony formation by either un-induced or tetracycline-induced MCF7tet-GRK2wt and -GRK2-K220R cells (B–D) or
by GRK2- or shRNA-GRK2-infected MDA-MB-231 cells (E) in soft-agar medium was analyzed as described in Materials and Methods. The area of colonies was measured using Image J
and the size of colonies was scored as Large, Medium and Small as described in Materials and Methods. Bar-graphs show the distribution (%) of the colonies according to their size (C,
E) and the median size (D) of colonies. Data are mean ± SD of 2 duplicate independent experiments. (*p b 0.05, **p b 0.01, ***p b 0.001). (F, G) The GRK2-HDAC6-Pin1 axis fosters
malignant growth of luminal and basal breast tumor cells. Soft agar colony formation of MCF7 cells (F) transiently co-transfected with either HA-Pin1-wt, HA-Pin1-K64R or HA-Pin1-
K46Q and speciﬁc Pin1 siRNAs or a control siRNA, as well as MDA-MB-231 cells (G) stably expressing either HDAC6-wt or the GRK2-deﬁcient phosphorylation mutant HDAC6-S1060-
1062-1068A in 96-multiwell plates was monitored by Alamar Blue staining as described in Materials and Methods. Data are mean ± SEM of 3 independent experiments performed by
triplicate. *p b 0.05, **p b 0.01, when compared to empty-vector or siRNA-control transfected cells in each condition and #p b 0.05, comparing HDAC6-wt with HDAC6 mutant.
Representative images of cellular foci are shown.
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stimulation of receptors (EGFR, HER2, ER) able to trigger AKT stimula-
tion (Renoir et al., 2013; Roskoski, 2014), which in turn can stabilize
GRK2 protein by means of hampering Mdm2-mediated GRK2 protea-
some degradation (Salcedo et al., 2006). However, the occurrence ofpost-transcriptional mechanisms cannot be ruled out, since canonical
transcriptional modulators as estrogens promoted GRK2 up-regulation
in ER+ MCF7 and T47D cells.
Importantly, GRK2 levels play a driving role in the acquisition of on-
cogenic features. GRK2 up-regulation in either untransformed or cancer
Fig. 6. GRK2 protein levels are up-regulated in a signiﬁcant proportion of breast cancer patients and positively correlate with relevant prognostic markers of tumor aggressiveness. GRK2
levels (A) and p-S473AKT (B)were analyzed bywestern blot in 27 samples from breast cancer patientswith inﬁltrating ductal carcinoma and 12 controls. Bars indicatemedian values. Pie
charts showgroup tumor patients based on the degree of change inGRK2 and p-AKT expression levels compared to an arbitrary control [(+), higher than control; (−), lower than control;
nc, within the range of normal variation (see Materials and Methods)]. (C, D) Samples of 49 patients were analyzed by immunohistochemistry to detect GRK2 and p-AKT. Samples were
scored as positive (moderate or strong staining, +) or negative (none or weak staining,−) for GRK2 and p-AKT levels (C). Samples were stratiﬁed by p-AKT levels and the distribution of
GRK2 groups plotted in a pie chart. Representative sections of GRK2 and p-AKT staining of two patients are shown in panel d. The distribution of tumor size (E), Ki67 (F) and p53 (G) in the
cohort of 27 patients with IDC was plotted according to GRK2 expression in a pie chart. p53 levels were determined by immunostaining and the remaining markers were obtained from
clinical data (+, presence;−, absence). (H, I) GRK2 correlation with Pin1 expression and its de-acetylation status. Levels of Pin1 and GRK2 were determined by western blot (+, higher
than control;−, lower than control; n.c, within the range of normal variation). Pie chart shows GRK2 distribution according to Pin1 expression (H). Pearson test was performed for
statistical analysis (C–H). The acetylation status of Pin1 (I) was determined by immunoprecipitation of Pin1 and subsequent immunoblotting with acetyl-lysine and Pin1 antibodies.
Pin1 acetylation ratio was plotted against GRK2 levels and the curve was ﬁtted into a quadratic regression linear model using the BestCurFit program.
141L. Nogués et al. / EBioMedicine 13 (2016) 132–145breast cells leads to a reinforcement of mitogenic (ERK1/2) and survival
(AKT) pathways and to increased expression of the proliferation medi-
ator Pin1, thereby enhancing growth potential under low-serum or nor-
mal conditions and resistance to the induction of cell death by different
therapeutic agents. Moreover, GRK2 up-regulation markedly favors an-
chorage-independent growth of MCF7 or MDA-MB-231 cells and in-
creases their competence to trigger tumor growth in vivo. Conversely,
decreasing GRK2 levels have the opposite effect in either MCF7, MDA-
MB-231 or MDA-MB-468 cells and sensitize cells to apoptotic stimuli,
indicative of a critical role for GRK2 in this process.
The pro-survival and proliferative effects of GRK2 reported herein
are clearly dependent on its kinase activity, since expression of GRK2-
K220R, a mutant that lacks catalytic activity, is not able to mimic the ef-
fects of the wild-type protein in vitro or in vivo. In this context, we put
forward the HDAC6-Pin1 axis and p53 as relevant direct and indirect
targets, respectively, underlying the effects of GRK2 on breast cancercells. We have reported that GRK2-mediated HDAC6 phosphoryla-
tion driven by phosphorylation of GRK2 itself at S670 in response
to EGF speciﬁcally enhances HDAC6-mediated de-acetylation activi-
ty and migration of epithelial cells (Lafarga et al., 2012a). We ﬁnd
that HDAC6 levels and (or) pS670-GRK2 are increased in the tested
breast cancer cells, wherein both proteins could interact with the
EGFR (Deribe et al., 2009; Evron et al., 2012; Gao et al., 2010;
Penela et al., 2010a) and modulate its signaling. Since HDAC6 poten-
tiates EGFR signaling by decreasing EGFR internalization (Deribe et
al., 2009; Gao et al., 2010), we hypothesize that the higher GRK2
and HDAC6 levels in luminal breast cancer cells would favor an en-
hanced local deacetylase turnover and more sustained signaling in
response to activation of EGFR and other ErbB family members
(Deribe et al., 2009), or ER alpha estrogen receptors, which interact
also with HDAC6 (Azuma et al., 2009) and promote GRK2-S670
phosphorylation (Dominguez et al., 2009).
Fig. 7. GRK2modulates in vivo tumor growth in a kinase-dependent manner by regulating proliferative and apoptotic pathways. (a) MCF7tet-GRK2wt or -GRK2-K220R cells pre-treated
with tetracycline or vehicle (control)were subcutaneously implanted in doxycycline-treated or un-treated (control) nudemice. Tumor volumewasmeasured and endpoint tumors were
immuno-stained for GRK2, Ki67, p53 and cleaved caspase-3 (b) as described inMaterials andMethods. (Scale bar: 100 μm). Data are themean± SEM from tumormasses of 6–8mice per
group. (c) Tumor growth was monitored (6–10mice per condition) in nudemice subcutaneously injected with MCF7 cells infected with the indicated adenoviral constructs and veriﬁed
for proper GRK2 levels by western blot. (d) Immunohistochemical analysis of GRK2, Ki67, p53 and annexin V expression in sections of tumors 8-days post-injection. (Scale bar: 100 μm).
(e) Analysis of the orthotopic growth of MCF7-F5luc cells stably expressing GRK2-wt or a silencing shRNA-GRK2 construct injected in the mammary fat pad of nude mice with Xenogen
imaging, using luciferin substrate once per week after implantation of cancer cells. Signals from primary breast tumors at 2, 4 and 6weeks after implantation are shown. Data aremean±
SEM from 3 to 5 mice per condition. In all panels *p b 0.05 or T p b 0.05, **p b 0.01, ***p b 0.001 compared to control condition.
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HDAC6 de-acetylates Pin1 at the residue K46 in a stimulus-dependent
manner. EGF triggers a rapid interaction of these proteins and the con-
current Pin1 de-acetylation is fostered by GRK2 expression through
HDAC6 modulation in different breast cancer cell types, whereas a cor-
relation between GRK2 expression and Pin1 levels and de-acetylation
status is detected in breast cancer patients. Importantly, the extent of
K46 acetylation has functional consequences, since a GRK2-mediatedde-acetylated status enhances Pin1 stability and also bolsters its func-
tionality, by increasing its afﬁnity toward a canonical peptide substrate,
its catalytic efﬁciency compared to acetylated Pin, and binding tomitot-
ic cellular substrates. There is compelling evidence for Pin1 substrate
binding involving the N-terminal WW domain (residues 1–39) and
the C-terminal PPIase region (residues 50–163) (Innes et al., 2013),
and for complex functional inter-domain interactions that impact both
on Pin1 catalytic activity and on binding afﬁnity and selectivity. Some
143L. Nogués et al. / EBioMedicine 13 (2016) 132–145targets such as PLK1 require simultaneous interactions with both the
WW and the PPIase domains, while the interaction of others relies ex-
clusively on the WW domain (Innes et al., 2013). The weaker binding
in the former situation is subsequently counterbalanced by the contri-
bution of the PPIase domain, which ligand afﬁnity is enhanced upon
WW domain occupancy. Both Pin1 functional domains are tethered
through a structurally disordered glycine-rich linker (residues 45–53)
located at the N-terminal portion of the PPIase region. Since the PPIase
domain is sensitive to inter-domain contacts that trigger allosteric com-
munication, the inter-domain linker might play an active role in such
process, by helping to position both domains in close contact and by in-
creasing the local concentration of substrate available to the PPIase ac-
tive site (Wilson et al., 2013). It is tempting to suggest that dynamic
acetylation-deacetylation-mediated variations in charge at the residue
K46 (conserved from humans to yeast) might alter the inter-domain
linker folding (perhaps via electrostatic interactions with the proximal
E52 residue), thus modulating inter-domain allosteric contacts and
thus Pin1 ligand afﬁnity and catalytic activity.
Potentiation of theHDAC6-Pin1 signalingmodule by GRK2 in specif-
ic breast cancer cells could be envisaged as an adaptation to enhanced
activity of different tumor-promoting cascades that would trigger a
self-perpetuating positive feedback cycle promoting cell proliferation
and increased survival. Notably, HDAC6 is required for oncogenic Ras-
and ErbB2-dependent ﬁbroblast transformation, for sustained ERK1/2
and AKT signaling, for anchorage-independent growth of MCF7 cells
and cancer cell survival (Lee et al., 2008; Li et al., 2013). Consistent
with a regulatory role of GRK2 on HDAC6 tumoral competences, we
ﬁnd that extra GRK2 levels lessen the cytotoxic effectiveness of
HDAC6 inhibitors (West and Johnstone, 2014). Therefore, it is tempting
to suggest that GRK2-mediated phosphorylation and activation of
HDAC6 makes this molecule less sensitive to its inhibitors, thereby de-
bilitating their therapeutic effects. Such notion would be consistent
with ineffective or partial responses shown by pan-HDAC inhibitors in
GRK2-overexpressing (MCF7, MDA-MB361) (Tate et al., 2012) and
with different efﬁcacies among breast tumor cells with p53mutant sta-
tus (Li et al., 2011) and different pS670-GRK2 ratios. Therefore, treat-
ment of certain types of breast cancer may beneﬁt from the combined
inhibition of GRK2 and HDAC6.
It is worth noting that the HDAC6's substrate Pin1, which levels are
over-expressed in human breast cancers (Ryo et al., 2003) and tran-
scriptionally enhanced by oncogenic HER2 or Ras signaling, is also crit-
ical for the HER2-Ras-triggered transformation of mammary epithelial
cells (Ryo et al., 2002), for EGF signaling andHER-2 expression in breast
cancer cells (Khanal et al., 2010), for regulation of the activity of estro-
gen receptors (Lucchetti et al., 2013), and for coordination of cell cycle
progression (Liou et al., 2011). By using silencing approaches and (or)
HDAC6 or Pin1mutants unable to undergo GRK2-mediated phosphory-
lation or de-acetylation, our data support a relevant role of the GRK2-
HDAC6-Pin1 signaling axis in reinforcing growth factor signaling, prolif-
eration and anchorage-independent growth. Since the higher growth
rates of breast tumor cells rely on Pin1 binding to cell-cycle associated
proteins (Khanal et al., 2010; Liou et al., 2011; Lucchetti et al., 2013;
Ryo et al., 2002), our data suggest that GRK2 would foster proliferation
by triggering HDAC6-mediated Pin1 deacetylation, leading to enhanced
interaction with mitotic regulators, particularly which those displaying
an allosteric binding mode such as PLK-1 or Cdc25 phosphatase (Innes
et al., 2013). Therefore, concurrent Pin1 and GRK2 up-regulation also
emerges as a relevant component of the tumorigenesis pathway.
On the other hand, the simultaneous GRK2-dependent down-modu-
lation of wild-type p53 protein and extra activation of the pro-survival
AKT route might also help to counteract the effects of relevant cytotoxic
compounds. We observe that down-regulating GRK2 levels increases
sensitivity to apoptotic agents in cultured cells and triggers a strong
p53 response in xenograft-derived tumors in vivo. Conversely, increas-
ing GRK2 expression in non-transformed breast cells reduces
genotoxic-dependent cell death and the p53 response, as previouslynoted in genotoxic cell cycle-arrested cells (Penela et al., 2010b).
These results are consistent with the occurrence of an inverse
GRK2-p53 correlation in the xenograft tumor model and in tumors
of patients with breast cancer scored as p53-negative (either by
gene-deletion or by protein down-modulation), suggesting that
GRK2might be an importantmodulator of the intact p53 pathway ei-
ther through direct modulation of HDAC6 (Tang et al., 2008) or of
other upstream regulators, with potential implications in therapy.
An important proportion of breast cancer ERα-+ patients treated
with estradiol antagonists or aromatase inhibitors become resistant
to these compounds, what urges to identify new therapeutic targets
(Renoir et al., 2013). We found that tamoxifen-resistant MCF7 cells
can build stronger apoptotic responses in the absence of GRK2, sug-
gesting that pharmacological inhibition of this kinase might be effec-
tive to inactivate tamoxifen-resistance pathways and to sensitize
cells to general chemotherapeutic agents.
Interestingly, GRK2 down-modulation similarly inhibited tumor
growth of breast tumor cell lines-derived xenografts irrespective of
their p53 status, suggesting that the ability of GRK2 to modulate
tumor development in vivo is independent of the p53 status or, alterna-
tively, that it has a double-edge sword role, attenuating p53's tumor-
suppressor functions in cells retaining the wild-type factor, but other-
wise promoting its oncogenic roles in contexts of mutant p53 expres-
sion. In this regard, mutant p53 stability and oncogenic gain-of-
function of p53 mutants relies on the presence of Pin1 (Girardini et al.,
2011) and HDAC6 (Li et al., 2011), which levels and activity are both
positively modulated by GRK2.
In sum, our data identify the GRK2 signaling node as a relevant play-
er in the development of breast cancer. GRK2 up-regulation emerges as
a convergent feature of the stimulation of diverse pathways altered in
luminal breast cancer, in parallel to that of other key proteins such as
HDAC6 or Pin1. In such conditions as well as in cellular settings of in-
creased phosphorylation of GRK2 on S670 bymeans of hyper-activation
of ERK1/2 or other kinases (often found in both luminal and basal tu-
moral contexts), the switch-on of the GRK2-HDAC6-Pin1 signaling
module would help to trigger a self-perpetuating positive feedback
loop of growth factor transduction cascades driving cell survival and
proliferation. GRK2 could also inhibit wild-type p53 in a AKT and
Mdm2-dependent manner in luminal cells, while in tumor cells with
mutant p53 GRK2 could act as an ampliﬁer of oncogenic p53 functions
by means of the increased functional competence of Ras-Pin1 and
HDAC6.
However, the pro-tumoral role of GRK2might bemore complex due
to the concurrent and opposite changes of GRK2 in the epithelial (up-
regulation) and stromal (down-modulation) components of breast tu-
mors. The down-modulation of GRK2 speciﬁcally in the surrounding
tumor endothelium results in vasculature dysfunction and hypoxia,
thereby impelling a more aggressive tumor progression (Rivas et al.,
2013). Therefore, a better knowledge of the mechanisms underlying
such cell type–speciﬁc modulation and roles of GRK2 may help to un-
derstand its integrated role in cancer development and to design future
therapeutic strategies.Funding Sources
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